Viscogliosi Brothers Acquisition Corp. (VBOCU) operates as a blank check company, or special purpose acquisition company, with no significant current operations; it focuses on pursuing mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or similar business combinations primarily targeting businesses in the neuro-musculoskeletal industry in North America and Europe. The company offers redeemable units comprising common stock and warrants exercisable at $11.50 per share, providing investors public market exposure to potential targets in implantable devices, services, regenerative medicine, and contract manufacturing within the healthcare sector. Incorporated in 2020 and headquartered in New York, New York, it completed a $75 million initial public offering in January 2022 through 7.5 million units priced at $10 each, underwritten by Raymond James, with an 18-month tenor to identify and complete a transaction. In July 2023, the company liquidated without completing a merger after shareholders declined a deadline extension, returning funds to investors and marking the end of its active SPAC phase.